Margaret M. Racke
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Amyloidosis: Diagnosis, Treatment, Outcomes, Neuroscience and Neuropharmacology Research, Neuroinflammation and Neurodegeneration Mechanisms
Most-Cited Works
- → A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms(1993)690 cited
- → A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice(2012)443 cited
- → Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β(2005)330 cited
- → Agonist-activated cobalt uptake identifies divalent cation—Permeable kainate receptors on neurons and glial cells(1991)217 cited
- → Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain.(1993)182 cited
- → Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes.(1993)94 cited
- → Isolation and cDNA sequence of human postheparin plasma hepatic triglyceride lipase.(1988)89 cited
- → A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics(2016)83 cited
- → ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo(2008)63 cited
- → Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models(2017)58 cited